Your browser is no longer supported. Please, upgrade your browser.
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E23.94 EPS (ttm)12.47 Insider Own0.10% Shs Outstand149.70M Perf Week-1.14%
Market Cap44.41B Forward P/E14.33 EPS next Y20.83 Insider Trans-6.95% Shs Float146.50M Perf Month-11.85%
Income1.92B PEG- EPS next Q4.16 Inst Own86.50% Short Float1.62% Perf Quarter-21.64%
Sales11.70B P/S3.80 EPS this Y-21.10% Inst Trans-1.36% Short Ratio1.92 Perf Half Y9.60%
Book/sh71.82 P/B4.16 EPS next Y11.52% ROA7.80% Target Price417.70 Perf Year8.40%
Cash/sh20.50 P/C14.56 EPS next 5Y-7.65% ROE17.90% 52W Range223.25 - 468.55 Perf YTD21.90%
Dividend- P/FCF16.79 EPS past 5Y10.10% ROI19.60% 52W High-36.29% Beta0.44
Dividend %- Quick Ratio1.80 Sales past 5Y4.50% Gross Margin83.90% 52W Low33.70% ATR7.91
Employees9100 Current Ratio2.10 Sales Q/Q-24.60% Oper. Margin18.90% RSI (14)27.04 Volatility1.99% 2.49%
OptionableYes Debt/Eq0.00 EPS Q/Q-68.80% Profit Margin16.40% Rel Volume0.72 Prev Close300.19
ShortableYes LT Debt/Eq0.68 EarningsJul 22 BMO Payout0.00% Avg Volume1.24M Price298.49
Recom2.30 SMA20-8.19% SMA50-10.10% SMA2001.05% Volume931,996 Change-0.57%
Jun-18-21Upgrade Piper Sandler Neutral → Overweight $384 → $450
Jun-14-21Reiterated Truist Buy $458 → $647
Jun-11-21Upgrade Bernstein Mkt Perform → Outperform $500
Jun-10-21Upgrade UBS Neutral → Buy
Jun-08-21Upgrade William Blair Mkt Perform → Outperform
Jun-08-21Upgrade Robert W. Baird Underperform → Neutral $216 → $382
Jun-08-21Upgrade Citigroup Sell → Neutral $200 → $440
Jun-08-21Upgrade Atlantic Equities Underweight → Neutral $415
Jun-08-21Reiterated Stifel Buy $346 → $446
Jun-08-21Reiterated RBC Capital Mkts Sector Perform $259 → $400
Jun-08-21Reiterated Morgan Stanley Overweight $343 → $455
Jun-08-21Reiterated Jefferies Buy $450 → $500
Jun-08-21Reiterated H.C. Wainwright Buy $305 → $452
Jun-08-21Reiterated Barclays Equal Weight $265 → $395
Jun-07-21Upgrade Raymond James Underperform → Mkt Perform
Jun-07-21Upgrade Cowen Market Perform → Outperform $225 → $450
Jun-07-21Upgrade BofA Securities Underperform → Neutral $235 → $400
Feb-05-21Downgrade DZ Bank Buy → Hold $264
Jan-29-21Upgrade Stifel Hold → Buy $258 → $358
Nov-10-20Upgrade DZ Bank Hold → Buy $265
Sep-20-21 05:50PM  
10:41AM  
08:00AM  
07:30AM  
Sep-17-21 10:58AM  
09:09AM  
Sep-16-21 01:20PM  
07:30AM  
06:09AM  
Sep-15-21 03:08PM  
07:30AM  
Sep-14-21 05:50PM  
Sep-10-21 08:08AM  
06:01AM  
Sep-09-21 07:01PM  
04:20PM  
04:16PM  
01:18PM  
Sep-04-21 11:45AM  
Sep-02-21 04:17PM  
11:27AM  
Sep-01-21 05:50PM  
Aug-31-21 10:53AM  
Aug-30-21 11:14AM  
06:00AM  
Aug-29-21 06:37AM  
Aug-27-21 11:22AM  
Aug-26-21 05:50PM  
11:48AM  
06:00AM  
12:35AM  
Aug-25-21 06:39AM  
Aug-24-21 06:55AM  
Aug-20-21 06:01AM  
Aug-19-21 09:49AM  
Aug-18-21 09:48AM  
Aug-17-21 05:55PM  
01:14PM  
02:12AM  
Aug-16-21 06:13PM  
Aug-13-21 05:00PM  
12:30PM  
06:59AM  
Aug-12-21 05:32PM  
07:53AM  
Aug-11-21 06:16PM  
03:15PM  
Aug-09-21 01:01PM  
11:04AM  
Aug-06-21 11:01AM  
Aug-05-21 10:15AM  
07:39AM  
Aug-04-21 03:25PM  
03:18AM  
Aug-03-21 05:50AM  
Aug-02-21 07:30AM  
Jul-31-21 07:03AM  
Jul-30-21 01:21PM  
12:31PM  
12:31PM  
07:02AM  
06:11AM  
Jul-29-21 06:56PM  
04:30PM  
04:10PM  
07:32AM  
06:25AM  
Jul-28-21 01:51PM  
Jul-27-21 04:19PM  
11:14AM  
06:29AM  
Jul-26-21 04:35PM  
04:10PM  
Jul-25-21 06:00AM  
03:28AM  
Jul-23-21 04:30PM  
Jul-22-21 11:00PM  
09:30PM  
04:10PM  
03:07PM  
02:11PM  
11:03AM  
10:27AM  
09:36AM  
08:25AM  
07:53AM  
07:20AM  
07:11AM  
07:11AM  
07:07AM  
07:06AM  
07:05AM  
06:38AM  
05:48AM  
04:22AM  
Jul-21-21 08:00PM  
03:39PM  
11:49AM  
08:33AM  
08:03AM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCDONNELL MICHAEL REVP, Chief Financial OfficerSep 01Option Exercise338.246,0052,031,1314,864Sep 03 04:08 PM
Sandrock AlfredHead of Research & DevelopmentJun 07Sale440.007,6723,375,68010,169Jun 09 07:05 PM
Guindo ChirfiHead of Glob Prod Strat & ComJun 07Sale440.003,0871,358,2802,919Jun 09 07:04 PM
Posner Brian SDirectorJun 04Sale274.1736098,7017,400Jun 07 07:02 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.004,454019,715Feb 17 05:01 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0016,289060,194Feb 17 05:03 PM
Kramer RobinSVP, Chief Accounting OfficerFeb 12Option Exercise0.003330706Feb 17 04:59 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.003,15606,946Feb 17 04:58 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.002,92309,288Feb 17 04:56 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,57304,765Feb 17 04:54 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.004,355043,509Feb 17 04:52 PM
Mantas Jesus BDirectorFeb 09Buy267.00898239,7662,943Feb 10 04:31 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00740395Dec 07 09:08 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0048104,004Dec 03 05:41 PM
Vounatsos MichelChief Executive OfficerNov 30Buy241.313,100748,04734,810Dec 01 04:57 PM
Sandrock AlfredEVP, Research & DevelopmentNov 04Sale350.001,500525,00013,066Nov 06 09:39 PM